Starling Oncology, Inc. STLN
$6.90
$0.274.00%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 9.39% | 3.86% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 9.39% | 3.86% | |||
| Cost of Revenue | 8.05% | 4.14% | |||
| Gross Profit | 16.51% | 2.42% | |||
| SG&A Expenses | 6.14% | 0.61% | |||
| Depreciation & Amortization | 13.74% | -0.98% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 7.76% | 3.42% | |||
| Operating Income | 29.13% | 5.70% | |||
| Income Before Tax | -292.82% | 66.81% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -292.82% | 66.81% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -292.82% | 66.81% | |||
| EBIT | 29.13% | 5.70% | |||
| EBITDA | 43.27% | 7.17% | |||
| EPS Basic | -288.35% | 67.46% | |||
| Normalized Basic EPS | -288.24% | 66.95% | |||
| EPS Diluted | -288.35% | 68.01% | |||
| Normalized Diluted EPS | -288.24% | 66.95% | |||
| Average Basic Shares Outstanding | 1.21% | 0.34% | |||
| Average Diluted Shares Outstanding | 1.21% | 0.34% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||